Highly aneuploid non-small cell lung cancer shows enhanced responsiveness to concurrent radiation and immune checkpoint blockade.
Spurr LF, Martinez CA, Kang W, Chen M, Zha Y, Hseu R, Gutiontov SI, Turchan WT, Lynch CM, Pointer KB, Chang P, Murgu S, Husain AN, Cody B, Vokes EE, Bestvina CM, Patel JD, Diehn M, Gajewski TF, Weichselbaum RR, Chmura SJ, Pitroda SP.
Spurr LF, et al. Among authors: gajewski tf.
Nat Cancer. 2022 Dec;3(12):1498-1512. doi: 10.1038/s43018-022-00467-x. Epub 2022 Nov 28.
Nat Cancer. 2022.
PMID: 36443406
Clinical Trial.